Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

DOI Web Site 2 Citations
  • Mark Roschewski
    Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Michail S. Lionakis
    Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
  • Jeff P. Sharman
    Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR, USA.
  • Joseph Roswarski
    Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Andre Goy
    John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ, USA.
  • M. Andrew Monticelli
    Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO, USA.
  • Michael Roshon
    Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO, USA.
  • Stephen H. Wrzesinski
    Department of Medicine, St. Peter’s Hospital and US Oncology, Albany, NY, USA.
  • Jigar V. Desai
    Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
  • Marissa A. Zarakas
    Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
  • Jacob Collen
    Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Keith M. Rose
    John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ, USA.
  • Ahmed Hamdy
    Acerta Pharma, South San Francisco, CA, USA.
  • Raquel Izumi
    Acerta Pharma, South San Francisco, CA, USA.
  • George W. Wright
    Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA.
  • Kevin K. Chung
    Department of Medicine, St. Peter’s Hospital and US Oncology, Albany, NY, USA.
  • Jose Baselga
    AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.
  • Louis M. Staudt
    Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Wyndham H. Wilson
    Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.

Description

<jats:p>Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.</jats:p>

Journal

  • Science Immunology

    Science Immunology 5 (48), eabd0110-, 2020-06-26

    American Association for the Advancement of Science (AAAS)

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top